PriceTargets.com logo

Calithera Biosciences - CALA Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 12/20/2024 04:31 PM ET
▼ -0.0005 (-83.33%)

This chart shows the closing price for CALA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Calithera Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CALA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CALA

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Calithera Biosciences in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.00.

This chart shows the closing price for CALA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Calithera Biosciences. This rating has held steady since October 2023, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/15/2022LADENBURG THALM/SH SHDowngradeBuy ➝ Neutral
11/15/2022Leerink PartnersDowngradeOutperform ➝ Market Perform
8/29/2022HC WainwrightUpgradeNeutral ➝ Buy$8.00
8/16/2022Leerink PartnersBoost TargetOutperform$18.00
5/11/2022LADENBURG THALM/SH SHLower Target$60.00 ➝ $30.00
4/4/2022Leerink PartnersLower TargetOutperform$60.00 ➝ $40.00
1/31/2022LADENBURG THALM/SH SHInitiated CoverageBuy$80.00
1/20/2022Leerink PartnersUpgradeMarket Perform ➝ Outperform$60.00
11/8/2021HC WainwrightDowngradeBuy ➝ Neutral
11/5/2021William BlairDowngradeOutperform ➝ Market Perform
8/9/2021HC WainwrightReiterated RatingBuy$80.00
5/10/2021HC WainwrightReiterated RatingBuy$80.00
1/5/2021Smith Barney CitigroupLower Target$200.00 ➝ $100.00
1/5/2021HC WainwrightLower TargetBuy$190.00 ➝ $80.00
1/5/2021Leerink PartnersDowngradeOutperform ➝ Market Perform$140.00 ➝ $40.00
8/11/2020Leerink PartnersLower TargetOutperform$180.00 ➝ $140.00
6/2/2020William BlairReiterated RatingBuy
5/11/2020CitigroupBoost TargetBuy$140.00 ➝ $200.00
5/8/2020HC WainwrightReiterated RatingBuy$140.00 ➝ $190.00
3/27/2020CitigroupLower TargetBuy$160.00 ➝ $140.00
3/27/2020Jefferies Financial GroupInitiated CoverageBuy$120.00
3/11/2020Leerink PartnersReiterated RatingOutperform
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Calithera Biosciences logo
Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $0.00
Low: $0.00
High: $0.00

50 Day Range

MA: N/A

52 Week Range

Now: $0.00
Low: $0.00
High: $0.12

Volume

8,365 shs

Average Volume

5,625 shs

Market Capitalization

$487.20

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Calithera Biosciences?

The following sell-side analysts have issued reports on Calithera Biosciences in the last year: StockNews.com.
View the latest analyst ratings for CALA.

What is the current price target for Calithera Biosciences?

0 Wall Street analysts have set twelve-month price targets for Calithera Biosciences in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Calithera Biosciences in the next year.
View the latest price targets for CALA.

What is the current consensus analyst rating for Calithera Biosciences?

Calithera Biosciences currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CALA.

What other companies compete with Calithera Biosciences?

Other companies that are similar to Calithera Biosciences include Ampio Pharmaceuticals, Comera Life Sciences, eFFECTOR Therapeutics, OncoSec Medical and 180 Life Sciences. Learn More about companies similar to Calithera Biosciences.

How do I contact Calithera Biosciences' investor relations team?

Calithera Biosciences' physical mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company's listed phone number is (650) 870-1000 and its investor relations email address is [email protected]. The official website for Calithera Biosciences is www.calithera.com. Learn More about contacing Calithera Biosciences investor relations.